{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:38Z","timestamp":1753891898092,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To define the impact of associated abnormalities on the efficacy of the novel subtropical guidelines for palivizumab prophylaxis on respiratory syncytial virus (RSV)-related hospitalizations in patients with hemodynamically significant congenital heart disease (hsCHD).<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> This prospective study enrolled every patient seen at a tertiary care center for hsCHD, who was born between 2014 and 2018 and received at least 1 dose of palivizumab, according to the subtropical guidelines. The patients were followed until the age of 2 years.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 772 patients (49% male) were enrolled. Cyanotic CHD was seen in 46% of patients, of whom 23% had associated abnormalities. Lung\/airway abnormalities (14%) were the most common followed by the genetic syndromes associated with CHD (7.3%). Among the 772 patients, RSV-related hospitalizations occurred in 3.2 and 2.2% children aged \u2264 12 and 13\u201324 months, respectively. Most of the RSV infections occurred in patients no longer satisfying the criteria for palivizumab prophylaxis. The patients with associated abnormalities but not the type of CHD, patient age, and patient sex were risk factors for RSV-related hospitalizations. The rates of RSV-related hospitalizations, admission to the intensive care unit, and endotracheal intubation were higher for patients with associated anomalies than for other patients before 24 months of age (10.2 vs. 4.0%, 67 vs. 33%, and 39 vs. 4.2%, <jats:italic>p<\/jats:italic> = 0.004, 0.06, 0.013, respectively).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Children with abnormalities, especially genetic syndromes and lung\/airway problems associated with CHD, are at high risk for RSV-related hospitalization. Our current subtropical guidelines for palivizumab prophylaxis in patients with hsCHD, should be revised to include the results of this study.<\/jats:p>","DOI":"10.3389\/fped.2021.756787","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T14:21:50Z","timestamp":1641392510000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Shuenn-Nan","family":"Chiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Tai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-An","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chuan","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Hwan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jou-Kou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in medicaid","volume":"137","author":"Boyce","year":"2000","journal-title":"J Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s10096-011-1529-y","article-title":"Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis","volume":"31","author":"Hervas","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1651-2227.2002.tb03282.x","article-title":"Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting","volume":"91","author":"Eriksson","year":"2002","journal-title":"Acta Paediatr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1542\/peds.2004-0224","article-title":"Economic analysis of palivizumab in infants with congenital heart disease","volume":"114","author":"Yount","year":"2004","journal-title":"Pediatrics."},{"key":"B6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jpeds.2009.11.062","article-title":"Prevalence of congenital heart disease at live birth in Taiwan","volume":"156","author":"Wu","year":"2010","journal-title":"J Pediatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1651-2227.2010.02059.x","article-title":"Meta-analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infection","volume":"100","author":"Pons","year":"2011","journal-title":"Acta Paediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40121-016-0142-x","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with congenital heart disease","volume":"6","author":"Checchia","year":"2017","journal-title":"Infect Dis Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","year":"1998","journal-title":"Pediatrics."},{"key":"B10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1542\/peds.2014-2783","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","year":"2014","journal-title":"Pediatrics."},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jpeds.2015.12.029","article-title":"Risk of respiratory syncytial virus infection in cyanotic congenital heart disease in a subtropical area","volume":"171","author":"Chiu","year":"2016","journal-title":"J Pediatr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jpeds.2017.11.044","article-title":"Efficacy of a novel palivizumab prophylaxis protocol for respiratory syncytial virus infection in congenital heart disease: a multicenter study","volume":"195","author":"Chiu","year":"2018","journal-title":"J Pediatr."},{"key":"B13","first-page":"87","article-title":"genetic aspects of congenital heart defects","volume-title":"Moss and Adams' Heart Disease in Infants, Children, and Adolescents","author":"Goldmuntz","year":"2016"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1017\/S1047951117000609","article-title":"CHD and respiratory syncytial virus: global expert exchange recommendations","volume":"27","author":"Tulloh","year":"2017","journal-title":"Cardiol Young."},{"key":"B15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s002460010103","article-title":"Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening","volume":"21","author":"Altman","year":"2000","journal-title":"Pediatr Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.athoracsur.2012.06.063","article-title":"Genetic syndromes and outcome after surgical repair of pulmonary atresia and ventricular septal defect","volume":"94","author":"Chen","year":"2012","journal-title":"Ann Thorac Surg."},{"key":"B17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ppul.22674","article-title":"Lower airway anomalies in children with CATCH 22 syndrome and congenital heart disease","volume":"48","author":"Wang","year":"2013","journal-title":"Pediatr Pulmonol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0152208","DOI":"10.1371\/journal.pone.0152208","article-title":"Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States nationally representative database, 1997-2012","volume":"11","author":"Doucette","year":"2016","journal-title":"PLoS ONE."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/apa.15641","article-title":"Hospitalisations due to respiratory syncytial virus infection in children with Down syndrome before and after palivizumab recommendation in Japan","volume":"110","author":"Okamoto","year":"2020","journal-title":"Acta Paediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00431-018-03308-1","article-title":"Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders","volume":"178","author":"Paes","year":"2019","journal-title":"Eur J Pediatr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/1874285801408010071","article-title":"Respiratory syncytial virus infection in high-risk infants - an update on palivizumab prophylaxis","volume":"8","author":"Resch","year":"2014","journal-title":"Open Microbiol J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jpeds.2018.08.006","article-title":"Hospitalization for respiratory syncytial virus in children with down syndrome less than 2 years of age: a systematic review and meta-analysis","volume":"203","author":"Mitra","year":"2018","journal-title":"J Pediatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/adc.2008.139188","article-title":"Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection","volume":"94","author":"Thorburn","year":"2009","journal-title":"Arch Dis Child."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e100981","DOI":"10.1371\/journal.pone.0100981","article-title":"A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan","volume":"9","author":"Chi","year":"2014","journal-title":"PLoS ONE."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0172512","DOI":"10.1371\/journal.pone.0172512","article-title":"Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses","volume":"12","author":"Friedman","year":"2017","journal-title":"PLoS ONE."},{"key":"B26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/INF.0000000000001357","article-title":"Comparing first- and second-year palivizumab prophylaxis in patients with hemodynamically significant congenital heart disease in the CARESS database (2005-2015)","volume":"36","author":"Li","year":"2017","journal-title":"Pediatr Infect Dis J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2217\/fca-2017-0096","article-title":"Respiratory virus prophylaxis in congenital heart disease","volume":"14","author":"Joshi","year":"2018","journal-title":"Future Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.prrv.2018.12.001","article-title":"Expert consensus on palivizumab use for respiratory syncytial virus in developed countries","volume":"33","author":"Luna","year":"2020","journal-title":"Paediatr Respir Rev."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.756787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T14:21:53Z","timestamp":1641392513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.756787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":28,"alternative-id":["10.3389\/fped.2021.756787"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.756787","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"article-number":"756787"}}